Demand for weight-loss drugs fuels global rise in counterfeits
Send a link to a friend
[October 20, 2023]
By Patrick Wingrove and Maggie Fick
(Reuters) - Extraordinary demand for Novo Nordisk’s Ozempic and other
drugs used for weight-loss is fueling a global surge in counterfeit
versions, according to Reuters interviews with law enforcement,
anti-counterfeiting and public health officials.
The U.S.-based Pharmaceutical Security Institute (PSI), an
industry-backed organization that counts drugmakers Novo Nordisk and Eli
Lilly as members, said it is working with agencies, including Europol,
Interpol and U.S. Homeland Security, as well as companies that help
identify counterfeit products such as Israel’s BrandShield.
Their combined efforts include opening inquiries into complaints of fake
drugs, trolling e-commerce and social media for purchase offers or
advertisements and teaching customs officials how to spot counterfeits.
Novo’s Ozempic, approved to treat diabetes, contains the active
ingredient semaglutide, which is also used in the company's weight loss
drug, Wegovy.
Both are being used by people seeking to shed pounds, as is Lilly’s
Mounjaro, which is currently approved for diabetes and expected to get a
green-light from the U.S. Food and Drug Administration to treat obesity
in the coming months. All three medicines are in short supply amid a
global obesity epidemic and high rates of diabetes.
“These weight loss drugs are a hot topic right now because they’re on TV
and getting a lot of media attention. If I’m a criminal organization,
that’s the next opportunity I go ahead and exploit,” said Jim Mancuso,
director of the U.S. Department of Homeland Security’s Intellectual
Property Rights Coordination Center.
Mancuso said the agency is also working with Europol, Interpol and
around 23 other law enforcement agencies on tracking weight-loss drugs
to quell what they believe could become the worst tide of counterfeit
lifestyle medicines since erectile dysfunction drugs like Viagra.
Though Novo stresses that its medicines Ozempic and Wegovy are indicated
for the treatment of diabetes and weight-loss, respectively, the weekly
injection drugs have become household names in America for their use
off-label as lifestyle treatments.
Novo said in a statement to Reuters that it works closely with PSI and
other organisations to “share data accurately and provide an informed
picture on the status of these crimes”, and collaborates with law
enforcement and other authorities.
Lilly said its strategy includes deterring major counterfeiters of its
products through investigations, internet monitoring and legal actions
and partnering with government and non-government organizations and
trade associations.
[to top of second column]
|
A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is
shown in this photo illustration in Oslo, Norway, September 1, 2023.
REUTERS/Victoria Klesty/Illustration/File Photo
'SO MANY CASES' Ozempic is the
biggest target so far in Europe, according to a Europol official who
requested anonymity because he was not authorized to speak. Fake
weight-loss drugs will be a key focus in the agency’s annual
counterfeit medicines report, due next year, the official said.
“We have counterfeit products and stolen products,” the official
said. “We have so many cases.”
Counterfeit Ozempic has already been found in at least 14 countries,
including the UK, Germany, Egypt and Russia. Several have issued
warnings to pharmacies and consumers to be vigilant about
counterfeits, since it is not clear what they actually contain.
Germany's federal drug regulator last week urged pharmacies and drug
distributors to be vigilant following the discovery of wholesale
batches of fake Ozempic.
Britain’s regulator, the Medicines and Healthcare products
Regulatory Agency (MHRA), then said on Wednesday that injection pens
falsely labeled as Ozempic had been identified at two UK
wholesalers.
A World Health Organization spokesperson said use of such drugs
could pose significant health risks.
"We will look online and if we find something that infringes
(obesity drug trademarks) we'll get it taken down,” said Yoav Keren,
BrandShield CEO. “Sometimes PSI and its members will do sample
purchases," he said. When a consumer buys those fakes, “what you get
are expired drugs, counterfeit drugs, or nothing,” he added.
An officer for Interpol said that counterfeit obesity drugs because
of their high prices are largely being sold in affluent countries,
including those in North America, Europe and the Middle East, unlike
most fake drugs that tend to be marketed in poorer regions.
MHRA said reports related to potentially falsified GLP-1s, the class
of drug that includes Wegovy, Ozempic and Eli Lilly’s diabetes drug
Mounjaro, had risen from two in 2022 to as many as 20 this year.
Ireland’s Health Products Regulatory Authority told Reuters that it
has confiscated 233 units of counterfeit semaglutide compared with
32 units in 2022.
(Reporting by Patrick Wingrove; Editing by Aurora Ellis)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |